Clinical Trial Update: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD [Phase 2, Phase 3]

View source ↗

Summary

A dose-ranging study evaluating the efficacy of Buntanetap in mild-to-moderate Alzheimer's disease (Phase 2/3) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Buntanetap

Snippet

Sponsor: Annovis Bio Inc. | Conditions: Alzheimer Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-04-29